(Press-News.org) Milan, Italy: New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their age or menopausal status.
The findings, presented at the 14th European Breast Cancer Conference (EBCC 14) today (Wednesday), add to information available on the effect of pembrolizumab in patients with early-stage breast cancer that is at high risk of recurring or spreading further, and that is oestrogen receptor positive (ER positive) and HER2 negative [1].
KEYNOTE-756 is an international trial, which has been running for eight years. It randomised 1278 patients to receive pembrolizumab or placebo in addition to neoadjuvant chemotherapy (given before surgery) followed by adjuvant (given after surgery) pembrolizumab or placebo in combination with an endocrine therapy. The patients had invasive ductal carcinoma (IDC), meaning the cancer had started to spread out of the milk ducts into the surrounding breast tissues.
Professor Javier Cortés, Director of the International Breast Cancer Centre in Barcelona, Spain, said: “We have already reported that there was a statistically significant increase in the pathological complete response rate in patients receiving pembrolizumab compared to those receiving the placebo. The pathological complete response rate, meaning that no cancer cells remained in the breast or lymph nodes, was 24.3% in patients treated with pembrolizumab compared to 15.6% in patients treated with the placebo.
“Now we can show that these pCR rates occurred regardless of the patients’ age or menopausal status. In patients younger than 50 years old, the pCR rate was 23.8% in those on pembrolizumab (76 out of 319 patients) compared to 16.9% (55 out of 326) for those receiving placebo, and was 24.7% (78 of 316 patients) versus 14.2% (45 of 317) respectively in those aged 50 or older. In pre-menopausal women, the pCR rate was 23.4% (83 out of 354 patients) versus 16.1% (57 out of 353) respectively, and in post-menopausal women, it was 24.8% (69 out of 278 patients) versus 14.6% (42 out of 287), respectively.
“We also found that adding pembrolizumab to neoadjuvant chemotherapy did not delay the time to surgery. The average time to surgery in both groups of patients was about a month. The average time after surgery to the start of adjuvant treatment was 1.2 months in both groups.”
The study found there were similar rates of breast-conserving surgery and mastectomy in both groups. Among the patients who had breast-conserving surgery, 41.3% (262 patients) received pembrolizumab and 43.7% (281 patients) received placebo. Among those who had a mastectomy, 55.3% (351 patients) were treated with pembrolizumab and 54.4% (350 patients) had the placebo.”
Tissue collected at the time of surgery was analysed to see if any cancer cells remained after the neoadjuvant treatment, known as residual cancer burden (RCB). Neoadjuvant pembrolizumab resulted in a lower RCB for more patients, regardless of how well the immunotherapy had blocked a protein called PD-L1, which also drives some breast cancers.
Pathology reports found that 35% of patients (222 patients) treated with pembrolizumab had no or very small amounts of cancer cells remaining (RCB 0-1) versus 23.6% of patients (152) receiving placebo. A moderate amount of RCB (RCB-2) was found in 40.8% of patients treated with pembrolizumab versus 45.3% (259 versus 291 patients), and extensive RCB (RCB-3) was found in 20.5% versus 28.9% of patients respectively (130 versus 186 patients).
When the researchers looked at the effect of pembrolizumab according to whether patients had cancer that was ER positive in less than 10% of cells or in 10% or more, they found that 64.7% of patients (22 out of 34) with less than 10%, who were treated with pembrolizumab, had an RCB status of 0-1, compared to 37.2% of patients treated with placebo (16 out of 43). In patients with 10% or more ER positive cells, 33.3% compared to 22.7% had an RCB 0-1 status (200 out of 601 patients versus 136 out of 600 patients respectively).
Dr Fatima Cardoso, Director of the Breast Unit of the Champalimaud Clinical Centre, Lisbon, Portugal, is the principal investigator for the trial. Speaking before EBCC 14, she said: “Keynote 756 trial showed that the addition of pembrolizumab to neoadjuvant chemotherapy significantly increased pathological response at the time of surgery, and this was true regardless of PD-L1 levels and oestrogen receptor positivity. However, we saw a bigger benefit with higher PD-L1 levels and in ER-low tumours.
“Keynote-756 is also the only trial that is powered to analyse the impact of immunotherapy in long-term outcomes for this subtype of breast cancer.”
Adverse events from the treatments were unchanged from previous reports from the trial and were consistent with what is known already about each regimen.
The trial continues to follow the patients, and information is being collected on survival rates and whether there are any recurrences of cancer or other related symptoms.
Professor Michail Ignatiadis from the Institut Jules Bordet in Brussels, Belgium, is Chair of the 14th European Breast Cancer Conference and was not involved in the research. He said: “We have heard more data from the KEYNOTE-756 trial about which ER positive / HER2 negative patient subgroups benefit most from pembrolizumab in terms of pathological complete response. Longer follow-up is needed in order to see whether the improvement in pCR rates will result in more patients living for longer without their disease recurring, and we look forward to these data in due course.”
(ends)
Abstract no: 4, “Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: Results from the phase 3 KEYNOTE-756 study”, Wednesday 20 March, Young Investigator Innovation Award and oral abstract session, 11:00-12:55 hrs CET, Silver room. https://cm.eortc.org/cmPortal/Searchable/ebcc14/config/Normal/#!sessiondetails/0000107210_0
[1] ER positive cancers have receptors on the cell surfaces for the hormone oestrogen that encourage breast cancer cells to grow. HER2 (human epidermal growth factor receptor 2) negative means the cancer cells do have high levels of HER2 receptors on their surfaces.
END
New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status
2024-03-20
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
UTA federal research projects add $38 million to economy
2024-03-19
The economic impact of federally sponsored research at The University of Texas at Arlington was $38 million in 2022, with expenditures spread among 725 unique vendors, according to a new report. Of that total, the University spent about $24 million on research-related goods and services in Texas.
The research dollars also supported the salaries of 1,562 people during this time—including 517 faculty and 746 students.
“Research at UTA helps solve some of society’s most important problems, and it is also a vital economic driver in our economy and in the careers of our students and researchers,” said Kate Miller, vice president of research and ...
Rice researchers develop 3D-printed wood from its own natural components
2024-03-19
Researchers at Rice University have unlocked the potential to use 3D printing to make sustainable wood structures, offering a greener alternative to traditional manufacturing methods.
Wood has historically been marred by wasteful practices generated during shaping processes, driving up costs and environmental impact. Now researchers in materials science and nanoengineering at Rice have developed an additive-free, water-based ink made of lignin and cellulose, the fundamental building blocks of wood. The ink can be used to produce architecturally ...
Machine learning used to classify fossils of extinct pollen
2024-03-19
In the quest to decipher the evolutionary relationships of extinct organisms from fossils, researchers often face challenges in discerning key features from weathered fossils, or with prioritizing characteristics of organisms for the most accurate placement within a phylogenetic tree. Enter neural networks, sophisticated algorithms that underlie today’s image recognition technology.
While previous attempts to utilize neural networks in classifying extinct organisms within phylogenetic trees have struggled, a new study, recently published in PNAS Nexus, heralds a significant breakthrough. The model has been trained ...
Researchers identify key regulators underlying regeneration in Drosophila
2024-03-19
Some animals possess the remarkable ability to regenerate lost structures, exemplified by a lizard regrowing its tail. However, this regenerative process must be tightly regulated by the body to ensure proper tissue organization and to prevent abnormal growths, such as cancer. Yet, the precise mechanisms underlying this regulation are not well known. In a recent study published in PLOS Genetics, researchers at the University of Illinois Urbana-Champaign have identified an RNA-regulator called Brat as a key player in restraining tissue regeneration through its modulation of downstream growth factors.
“There are constraints and protective factors that are important for ...
HIV in cell culture can be completely eliminated using CRISPR-Cas gene editing technology, increasing hopes of cure
2024-03-19
**Note: the release below is a special early release from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024, Barcelona, Spain, 27-30 April). Please credit the congress if you use this story**
New research presented early ahead of this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024, Barcelona, 27-30 April) from a team of researchers in the Netherlands shows how the latest CRISPR-Cas gene editing technology can be used to eliminate all ...
UT researchers investigate how freshwater diatoms stay in the light
2024-03-19
Spring weather brings welcome conditions for flowers and plant life to bloom across the land. The right mixture of temperature, moisture, and light helps keep the green world vibrant.
Underwater plant life generally responds to similar environmental encouragements, but a curious discovery in Lake Erie circa 2012 led microbiologists to study an unseasonal display of winter abundance. Blooms of diatoms—microscopic, photosynthetic algae—were alive and well beneath (and within) the lake’s ...
Cape Lion was genetically diverse prior to extinction, researchers find
2024-03-19
Cape lions used to roam the Cape Flats grassland plains of South Africa, in what is now known as Western Cape Providence. When Europeans arrived in South Africa in the mid-1600s, Cape lions, along with many other African carnivores and herbivores, were hunted as agricultural practice to protect livestock and humans. By the mid-1800s, less than 200 years since European arrival, Cape lions had been hunted to extinction.
European naturalists described the Cape lion as having a particularly black mane and as being morphologically distinct. However, alternative depictions and descriptions of Cape ...
U.S. could cut cervical cancer cases & deaths by up to 20% if more patients got follow-up after screening, study suggests
2024-03-19
Getting screened for cervical cancer isn’t fun. And getting an alert that your initial exam showed a potential sign of trouble, and that you need to go back for a test or procedure to rule out cancer, is even less fun.
Plus, those follow-up procedures can cost hundreds of dollars, even though a law makes the initial cervical cancer screening test free to all eligible patients.
So it’s no wonder that many of those eligible don’t get screened in the first place – and that among those who get screened and have initial abnormal ...
Pushing the limit of the periodic table with superheavy elements
2024-03-19
Scientists from Massey University in New Zealand, the University of Mainz in Germany, Sorbonne University in France, and the Facility for Rare Isotope Beams (FRIB) discuss the limit of the periodic table and revising the concept of the “island of stability” with recent advances in superheavy element research. Their work is the cover feature of the February 2024 Nature Review Physics.
In addition to the Nature Reviews Physics feature, Physics Reports published a review on the atomic electronic structure theory for superheavy elements.
What is the heaviest bound nucleus ...
Synthetic dimension dynamics to manipulate light
2024-03-19
In the realm of physics, synthetic dimensions (SDs) have emerged as one of the frontiers of active research, offering a pathway to explore phenomena in higher-dimensional spaces, beyond our conventional 3D geometrical space. The concept has garnered significant attention, especially in topological photonics, due to its potential to unlock rich physics inaccessible in traditional dimensions. Researchers have proposed various theoretical frameworks to study and implement SDs, aiming at harnessing phenomena like synthetic gauge fields, quantum Hall physics, discrete solitons, and topological phase transitions in four dimensions or higher. Those proposals ...